


Curriculum Vitae

	Name in Full	Hana Alguel
	Country	Germany
	Affiliation	Comprehensive Cancer Center Munich, Klinikum rechts der Isar, Technical University of Munich
	Email	hana.alguel@mri.tum.de

Educational Background		
Institution name	Qualification	Year
II. Medical Department, Klinikum rechts der Isar, TUM	Gastroenterology	10/2011
II. Medical Department, Klinikum rechts der Isar, TUM	Gastrointestinal Oncology (AGIO)	04/2009
Bayerische Landesärztekammer	Board Certificate "Internal Medicine"	10/2008
II. Medical Department, Klinikum rechts der Isar, TUM	Principal Investigator of the scientific group "inflammation and cancer in the pancreas"	2007
Stuttgart	Accreditation	01/2002

Professional Career			
Position	Institution name and Department	Start Year	End Year
Director	Comprehensive Cancer Center Munich Technical University of Munich (TUM)	05/19	ongoing
Director	Institute for Tumor Metabolism	03/17	ongoing
Head of the Infectious Disease Unit	II. Medical Department, Klinikum rechts der Isar, TUM	05/2013	05/19
Head of the Gastro- intestinal Oncology Unit	II. Medical Department, Klinikum rechts der Isar, TUM	02/2013	ongoing

Senior Consultant	II. Medical Department, Klinikum rechts der Isar, TUM	05/2009	05/19
Resident	II. Medical Department, Klinikum rechts der Isar, TUM	01/2003	04/2009
Resident	Internal Medicine I, University of Ulm	06/2000	12/2002

Research Field

Translational Oncology

Inflammation associated Carcinogenesis in the Pancreas

Targeted Therapy in Pancreatic Cancer

Acute and Chronic Inflammation in the Pancreas

- Seufferlein T, Uhl W, Kornmann M, Algul H, Friess H, Konig A, et al. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer group. *Ann Oncol* 2023;34:91-100.
- Wang X, Istvanffy R, Ye L, Teller S, Laschinger M, Diakopoulos KN, et al. Phenotype screens of murine pancreatic cancer identify a Tgfa-Ccl2-paxillin axis driving human-like neural invasion. *J Clin Invest* 2023.
- Alonso-Nocelo M, Ruiz-Canas L, Sancho P, Gorgulu K, Alcalá S, Pedrero C, et al. Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma. *Gut* 2023;72:345-59.
- Frank KJ, Mulero-Sanchez A, Berninger A, Ruiz-Canas L, Bosma A, Gorgulu K, et al. Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer. *Cell Rep Med* 2022;3:100815.
- Kindler HL, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer. *J Clin Oncol* 2022;40:3929-39.
- Ai J, Wormann SM, Gorgulu K, Vallespinos M, Zagorac S, Alcalá S, et al. Bcl3 Couples Cancer Stem Cell Enrichment With Pancreatic Cancer Molecular Subtypes. *Gastroenterology* 2021;161:318-32 e9.
- Kabacaoglu D, Ruess DA, Gorgulu K, Steiger K, Lesina M, Algul H. A Pancreas-Specific Ptf1a-Driven Cre Mouse Line Causes Paternally Transmitted Germline Recombination. *Gastroenterology* 2021;161:1695-7 e4.
- Gorgulu K, Diakopoulos KN, Ai J, Schoeps B, Kabacaoglu D, Karpathaki AF, et al. Levels of the Autophagy-Related 5 Protein Affect Progression and Metastasis of Pancreatic Tumors in Mice. *Gastroenterology* 2019;156:203-17 e20.
- Ruess DA, Heynen GJ, Ciecieski KJ, Ai J, Berninger A, Kabacaoglu D, et al. Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase. *Nat Med* 2018;24:954-60.

10. Lesina M, Wormann SM, Morton J, Diakopoulos KN, Korneeva O, Wimmer M, et al. RelA regulates CXCL1/CXCR2-dependent oncogene-induced senescence in murine Kras-driven pancreatic carcinogenesis. *J Clin Invest* 2016;126:2919-32.